Remetinostat

DB14869InvestigationalSmall molecule

Remetinostat is under investigation in clinical trial NCT02213861 (Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma).

Mechanism: Pharmacologically active on Histone deacetylase
Curator reviewed
Formula / weight: C₁₆H₂₁NO₆ · 323.345 g/mol (avg)
Code names: SHP-141

Resolves to

Compound

UNII37NT056AT4CAS946150-57-8ChEMBLCHEMBL3707219

Structure

InChIKeyXDZAHHULFQIBFE-UHFFFAOYSA-NSMILESCOC(=O)C1=CC=C(OC(=O)CCCCCCC(=O)NO)C=C1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which companies are running trials of Remetinostat, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account